A3

4. (Amended) A peptide according to [any one of Claims 1 to 3] Claim 1 wherein the peptide is capable of binding to HLA-A0201.

6. (Amended) A peptide according to [any one of Claims 1 to 5] Claim 1 wherein the peptide includes non-peptide bonds.

SUB B2

7. (Amended) A peptide according to Claim 1 consisting of the amino acid sequence RMFPNAPYL (SEQ ID NO:1).

A4

8. (Amended) A peptide according to Claim 1 consisting of the amino acid sequence CMTWNQMNL (SEQ ID NO:2).

9. (Amended) A peptide according to Claim 1 consisting of the amino acid sequence HLMPFPGPLL (SEQ ID NO:3).

10. (Amended) A polynucleotide encoding a peptide according to [anyone of Claims 1 to 5 and 7 to 9] Claim 1.

A5 Cmt

12. (Amended) An expression vector capable of expressing a [polypeptide] peptide according to [any one of Claim 1 to 5 and 7 to 9] Claim 1.

13. (Amended) A host cell comprising a polynucleotide [according to Claim 10 or 11] encoding a peptide according to Claim 1, or an expression vector [according to Claim 12] capable of expressing the peptide.

14. (Amended) A method of producing a peptide, [according to any one of Claims 1 to 5 and 7 to 9] the method comprising culturing the host cell according to Claim 13 and obtaining the peptide from the host cell or its culture medium.

15. (Amended) A pharmaceutical composition comprising a peptide according to [any one of Claims 1 to 9] Claim 1 and a pharmaceutically acceptable carrier.

16. (Amended) A pharmaceutical composition comprising a polynucleotide [according to Claim 10 or 11] encoding a peptide according to Claim 1, or an expression vector [according to Claim 12] capable of expressing the peptide, and a pharmaceutically acceptable carrier.

17. (Amended) A method of treating a patient, the method comprising administering a peptide according to [any one of Claims 1 to 9 for use in medicine] Claim 1 to a patient.

18. (Amended) A method of treating a patient, the method comprising administering a polynucleotide [according to Claim 10 or 11] encoding a peptide according to Claim 1, or an expression vector [according to Claim 12 for use in medicine] capable of expressing the peptide, to a patient.

19. (Amended) A cancer vaccine comprising a peptide according to [any one of Claims 1 to 9 or] Claim 1, a polynucleotide [according to Claim 10 or 11] encoding the peptide, or an expression vector [according to Claim 12] capable of expressing the peptide.

20. (Amended) A method of killing target cells in a patient, which target cells aberrantly express a polypeptide comprising [an] the amino acid sequence [given in any of Claims 1 to 3]

RMFPNAPYL (SEQ ID NO:1), the amino acid sequence CMTWNQMNL (SEQ ID NO:2), or the amino acid sequence HLMPFRGPLL (SEQ ID NO:3), the method comprising administering to the patient an effective amount of a peptide according to [any one of Claims 1 to 9 or] Claim 1, a polynucleotide [according to Claim 10 or 11] encoding the peptide, or an expression vector [according to Claim 12] capable of expressing the peptide wherein the amount of said peptide or amount of said polynucleotide or amount of said expression vector is effective to provoke an anti-target cell immune response in said patient.

22. (Amended) A method for producing activated cytotoxic T lymphocytes (CTL) *in vitro*, the method comprising contacting i*n vitro* CTL with antigen-loaded human class I MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate, in an antigen specific manner, [said] the CTL wherein the antigen is a peptide according to [any one of Claims 1 to 9] Claim 1.

25. (Amended) A method according to [any one of Claims 22 to 24] Claim 22 wherein the antigen is loaded onto class I MHC molecules expressed on the surface of a suitable antigen-presenting cell by contacting a sufficient amount of the antigen with an antigen-presenting cell wherein before contact the class I MHC molecules of the antigen-presenting cell are substantially unoccupied and after contact the class I MHC molecules are substantially fully occupied.

26. (Amended) A method according to [any of Claims 22 to 24] Claim 22 wherein the antigen-presenting cell comprises an expression vector [according to Claim 12] capable of

encoding a peptide comprising the amino acid sequence RMFPNAPYL (SEQ ID NO:1), the amino acid sequence CMTWNQMNL (SEQ ID NO:2), the amino acid sequence HLMPFPGPLL (SEQ ID NO:3), or a portion or variant thereof provided that the peptide is not intact human WT-1 polypeptide and is not intact human gata-1 polypeptide.

27. (Amended) A method according to [any one of Claims 22 to 26] Claim 22 wherein the class I MHC molecule is HLA-A0201.

A7 cmcd.

28. (Amended) Activated cytotoxic T lymphocytes (CTL) obtainable by the method according to [any one of Claims 22 to 27] Claim 22.

29. (Amended) Activated cytotoxic T lymphocytes (CTL) which selectively recognise a cell which aberrantly expresses a polypeptide comprising an amino acid sequence given in [any one of Claims 1 to 3] Claim 1.

30. (Amended) A T-cell receptor (TCR) which recognises a cell which aberrantly expresses a polypeptide comprising [an] the amino acid sequence [given in any one of Claims 1 to 3] RMFPNAPYL (SEQ ID NO:1), the amino acid sequence CMTWNQMNL (SEQ ID NO:2), or the amino acid sequence HLMPFPGPLL (SEQ ID NO:3), the TCR being obtainable from the cytotoxic T lymphocyte (CTL) [of Claims 28 or 29] obtainable by the method according to Claim 22, or a functionally equivalent molecule to the TCR.

A8 cm.t

33. (Amended) A method of killing target cells in a patient which target cells aberrantly express a polypeptide comprising [an] the amino acid sequence [given in any one of Claims 1 to

3] RMFPNAPYL (SEQ ID NO:1), the amino acid sequence CMTWNQMNL (SEQ ID NO:2), or the amino acid sequence HLMPFPGPLL (SEQ ID NO:3), the method comprising administering to the patient an effective number of cytotoxic T lymphocytes (CTL) as defined in [Claims 28 or 29] Claim 28.

34. (Amended) A method of killing target cells in a patient, which target cells aberrantly express a polypeptide comprising [an] the amino acid sequence [given in any one of Claims 1 to 3] RMFPNAPYL (SEQ ID NO:1), the amino acid sequence CMTWNQMNL (SEQ ID NO:2), or the amino acid sequence HLMPFPGPLL (SEQ ID NO:3), the method comprising the steps of (1) obtaining cytotoxic T lymphocytes (CTL) from the patient; (2) introducing into [said] the cells a polynucleotide encoding a T cell receptor (TCR), or a functionally equivalent molecule, as defined in Claim 30; (3) introducing the cells produced in step (2) into the patient.

35. (Amended) A method of killing target cells in a patient which target cells aberrantly express a polypeptide comprising [an] the amino acid sequence [given in any one of Claims 1 to 3] RMFPNAPYL (SEQ ID NO:1), the amino acid sequence CMTWNQMNL (SEQ ID NO:2), or the amino acid sequence HLMPFPGPLL (SEQ ID NO:3), the method comprising the steps of (1) obtaining dendritic cells from said patient; (2) contacting said dendritic cells with a peptide as defined in [any one of Claims 1 to 9 or which] Claim 1, with a polynucleotide encoding the peptide, or with an expression vector [according to Claim 10 to 12] capable of expressing the peptide *ex vivo*; and (3) reintroducing the so treated dendritic cells into the patient.

36. (Amended) A method of killing target cells in a patient according to [any one of] Claim 20 [or 33 to 35] wherein the target cells are cancer cells.

37. (Amended) A method according to Claim 36 wherein the cancer is any one of a leukaemia, breast cancer, melanoma and ovarian cancer which aberrantly expresses the WT1 polypeptide which comprises the amino acid sequences RMFPNAPYL (SEQ ID NO:1) and CMTWNQMNL (SEQ ID NO:2).

38. (Amended) A method according to Claim 36 wherein the cancer is a leukaemia which aberrantly expresses the gata-1 polypeptide which comprises the amino acid sequence HLMPFPGPLL (SEQ ID NO:3).

Please cancel claims 2, 3, 21, and 39-42.

Remarks

Claims 1, 4-20, and 22-38 are pending. Claims 2, 3, 21, and 39-42 have been canceled. Claims 1, 4, 6-10, 12-20, 22, 25-30, and 33-38 have been amended. The claims have been amended to avoid multiple dependent claims, conform to U.S. practice, and to annotate amino acid sequences appearing in the claims. Claim 1 has been amended to incorporate the subject matter of claims 2 and 3. Claim dependencies have been amended in claims 4, 6-10, 12-20, 22, 25-36. The peptide definition of claims 1, 2, and/or 3 have been incorporated into claims 20, 26, 30, and 33-35. Claims 1, 7-9, 20, 26, 30, 33-35, 37, and 38 have been amended to annotate amino acid sequences with SEQ ID NOs. All of these amendments are supported at least by the